Oncopeptides AB (ONCO) - Total Liabilities

Latest as of September 2025: Skr204.74 Million SEK ≈ $22.03 Million USD

Based on the latest financial reports, Oncopeptides AB (ONCO) has total liabilities worth Skr204.74 Million SEK (≈ $22.03 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Oncopeptides AB operating cash flow efficiency to assess how effectively this company generates cash.

Oncopeptides AB - Total Liabilities Trend (2014–2024)

This chart illustrates how Oncopeptides AB's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Oncopeptides AB to evaluate the company's liquid asset resilience ratio.

Oncopeptides AB Competitors by Total Liabilities

The table below lists competitors of Oncopeptides AB ranked by their total liabilities.

Company	Country	Total Liabilities
Orad-M TA:ORAD	Israel	ILA84.18 Million
Urbanise.com Ltd AU:UBN	Australia	AU$12.05 Million
Milux Corporation Bhd KLSE:7935	Malaysia	RM30.37 Million
Biohit Oyj B HE:BIOBV	Finland	€4.90 Million
MUI Properties Bhd KLSE:3913	Malaysia	RM330.46 Million
Veru Inc NASDAQ:VERU	USA	$10.44 Million
Hipay Group SA PA:ALHYP	France	€173.68 Million
OTRS AG F:TR9	Germany	€7.20 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Oncopeptides AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Oncopeptides AB worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.42	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	31.32	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.97	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oncopeptides AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oncopeptides AB (2014–2024)

The table below shows the annual total liabilities of Oncopeptides AB from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr189.91 Million ≈ $20.44 Million	+4.58%
2023-12-31	Skr181.60 Million ≈ $19.54 Million	+99.49%
2022-12-31	Skr91.03 Million ≈ $9.80 Million	-60.16%
2021-12-31	Skr228.51 Million ≈ $24.59 Million	-38.22%
2020-12-31	Skr369.86 Million ≈ $39.80 Million	+88.25%
2019-12-31	Skr196.47 Million ≈ $21.14 Million	+52.66%
2018-12-31	Skr128.70 Million ≈ $13.85 Million	+108.19%
2017-12-31	Skr61.82 Million ≈ $6.65 Million	+111.01%
2016-12-31	Skr29.30 Million ≈ $3.15 Million	+318.39%
2015-12-31	Skr7.00 Million ≈ $753.53K	+26.91%
2014-12-31	Skr5.52 Million ≈ $593.73K	--

About Oncopeptides AB

ST:ONCO Sweden Biotechnology

Market Cap

$36.29 Million

Skr337.17 Million SEK

Market Cap Rank

#23054 Global

#433 in Sweden

Share Price

Skr1.30

Change (1 day)

-0.53%

52-Week Range

Skr1.30 - Skr6.31

All Time High

Skr343.59